Skip to main content

Table 1 Demographic data and clinical characteristics among septic patients with and without SLE

From: Impact of systemic lupus erythematosus on the 5-year survival of critically ill septic patients

  SLE Non-SLE p value
(n = 513) (n = 2052)
Age, years 48.8 ± 16.3 48.8 ± 16.3 1
Gender    1
 Female 442 (86.2) 1768 (86.2)  
 Male 71 (13.8) 284 (13.8)  
Urbanisation levels    < 0.001
 Urban 164 (32.0) 475 (23.1)  
 Suburban 221 (43.1) 947 (46.2)  
 Rural 128 (25.0) 630 (30.7)  
Low insured incomea 243 (47.4) 1141 (55.6) < 0.001
CCI without renal disease, mean ± SD 2.9 ± 1.7 2.4 ± 2.6 < 0.001
CCI without renal disease, group    < 0.001
 0 4 (0.8) 608 (29.6)  
 1–3 359 (70.0) 930 (45.3)  
 > 3 150 (29.2) 514 (25.0)  
Recent hospitalised infectionb 78 (15.2) 199 (9.7) < 0.001
Medications    
Glucocorticoid use 506 (98.6) 1606 (78.3) < 0.001
Glucocorticoid dosage, mg/dayc 47.9 ± 85.1 15.7 ± 40.2 < 0.001
Glucocorticoid dosage groupc    < 0.001
 0 mg/day 7 (1.4) 447 (21.8)  
 0-5 mg/day 27 (5.3) 678 (33.0)  
 ≥ 5 mg/day 479 (93.4) 927 (45.2)  
DMARD    
 Methotrexate 20 (3.9) 45 (2.2) 0.032
 Sulfasalazine 10 (1.9) 14 (0.7) 0.014
 Hydroxychloroquine 331 (64.5) 36 (1.8) < 0.001
 Immunosuppressantsd 294 (57.3) 98 (4.8) < 0.001
  1. aInsured income lower than median income (21,900 New Taiwan dollars). bWithin 3 months prior to index admission. cPrednisolone equivalent. dCyclophosphamide, azathioprine, cyclosporine, mycophenolate, and mycophenolic. Abbreviations: SLE Systemic lupus erythematosus, CCI Charlson comorbidity index, DMARD Disease-modifying antirheumatic drug